Neoadjuvant therapy for gastroesophageal adenocarcinoma

Emmanuelle Samalin, Marc Ychou

Emmanuelle Samalin, Marc Ychou, Digestive Oncology Department, Institut régional du Cancer de Montpellier (ICM), 34298 Montpellier, France

Author contributions: Both Samalin E and Ychou M designed the review and defined the plan and the issues discussed; Samalin E wrote the manuscript; Samalin E and Ychou M revised the manuscript and approved the final version.

Conflict-of-interest statement: Emmanuelle Samalin has received fees for serving as consultant for Roche and Lilly laboratories. Marc Ychou has received fees for serving as consultant for Roche, Lilly and Bayer laboratories.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Correspondence to: Emmanuelle Samalin, MD, Digestive Oncology Department, Institut régional du Cancer de Montpellier (ICM), 208 avenue des Apothicaires, 34298 Montpellier, France. emmanuelle.samalin@icm.unicancer.fr
Telephone: +33-4-67613136
Fax: +33-4-67613022

Received: July 29, 2015
Peer-review started: July 31, 2015
First decision: September 28, 2015
Revised: March 24, 2016
Accepted: April 7, 2016
Article in press: April 11, 2016
Published online: June 10, 2016

Abstract

Gastric and esophageal adenocarcinomas are one of the main causes of cancer-related death worldwide. While the incidence of gastric adenocarcinoma is decreasing, the incidence of gastroesophageal junction adenocarcinoma is rising rapidly in Western countries. Considering that surgical resection is currently the major curative treatment, and that the 5-year survival rate highly depends on the pTNM stage at diagnosis, gastroesophageal adenocarcinoma management is very challenging for oncologists. Several treatment strategies are being evaluated, and among them systemic chemotherapy, to decrease recurrences and improve overall survival. The MAGIC and FNCLCC-FFCD trials showed a survival benefit of perioperative chemotherapy in patients with operable gastric and lower esophageal cancer, and these results had an impact on the European clinical practice. New strategies, including induction chemotherapy followed by preoperative chemoradiotherapy, targeted therapies in combination with perioperative chemotherapy and the new cytotoxic regimens, are currently assessed to improve current standards and help developing patient-tailored therapeutic interventions.

Key words: Gastric adenocarcinoma; Lower esophagus adenocarcinoma; Gastroesophageal junction adenocarcinoma; Preoperative treatment; Neoadjuvant treatment

Correspondence to: Emmanuelle Samalin, MD, Digestive Oncology Department, Institut régional du Cancer de Montpellier (ICM), 208 avenue des Apothicaires, 34298 Montpellier, France. emmanuelle.samalin@icm.unicancer.fr
Telephone: +33-4-67613136
Fax: +33-4-67613022

Received: July 29, 2015
Peer-review started: July 31, 2015
First decision: September 28, 2015
Revised: March 24, 2016
Accepted: April 7, 2016
Article in press: April 11, 2016
Published online: June 10, 2016

Abstract

Gastric and esophageal adenocarcinomas are one of the main causes of cancer-related death worldwide. The incidence of gastroesophageal junction adenocarcinoma is rapidly rising in Western countries. Surgical resection is currently the major curative treatment. As the 5-year survival rate highly depends on the pTNM stage, the treatment strategy is very challenging for oncologists. Several treatments, including systemic chemotherapy, are being assessed to prevent recurrences and improve overall survival. New strategies, such as induction chemotherapy followed by preoperative chemoradiotherapy, targeted therapies and the new cytotoxic regimens in perioperative chemotherapy, are currently assessed to improve current standards and develop more tailored therapeutic interventions.

Core tip: Gastric and esophageal adenocarcinomas are one of the main causes of cancer-related death worldwide. The incidence of gastroesophageal junction adenocarcinoma is rapidly rising in Western countries. Surgical resection is currently the major curative treatment. As the 5-year survival rate highly depends on the pTNM stage, the treatment strategy is very challenging for oncologists. Several treatments, including systemic chemotherapy, are being assessed to prevent recurrences and improve overall survival. New strategies, such as induction chemotherapy followed by preoperative chemoradiotherapy, targeted therapies and the new cytotoxic regimens in perioperative chemotherapy, are currently assessed to improve current standards and develop more tailored therapeutic interventions.
INTRODUCTION
Survival of patients with esophageal, gastric or gastroesophageal junction adenocarcinoma is poor because they are frequently locally-advanced or with distant metastases at diagnosis. Even if the incidence of gastric adenocarcinoma is decreasing, it stays the second most frequent cause of cancer-related death worldwide. In 2012, 952,000 new cases of gastric cancer were diagnosed with 72,300 estimated deaths worldwide. In Western countries, a faster increase of the incidence of gastroesophageal junction adenocarcinoma compared to that of other gastrointestinal adenocarcinomas has been reported over the last 25 years. Surgical resection of the primary tumor is the major curative treatment for these upper gastrointestinal cancers. Esophageal cancers can be treated with exclusive radiochemotherapy, but this review will focus on (neo)adjuvant therapies. The 5-year survival rate is correlated with the pTNM stage, lymph node metastases being the major poor prognostic factor. A 5-year survival of 20% to 30% is reported in localized tumors, which extend beyond the submucosa. Also, gastroesophageal adenocarcinomas (GEA) are often detected at an already advanced stage, in Western countries, about 30% of resectable patients were not identified at an early stage. For this group, the rate of recurrence following resection of a gastric cancer is high. Currently, various strategies (including nutritional management) are developed and tested to reduce this risk and improve patient’s survival.

ADJUVANT THERAPIES FOR GASTROESOPHAGEAL ADENOCARCINOMA
Adjuvant chemotherapy
Like in colorectal cancer, adjuvant systemic therapy in patients with GEA is used to treat post-resection occult residual micro-metastatic disease and to increase survival. Many clinical studies have investigated the possible positive impact of adjuvant therapy on the patients’ outcomes. Between 1994 and 2002, meta-analyses of the data from these trials suggested that adjuvant chemotherapy slightly increases overall survival, with a reduction of the risk of death between 12% and 18%. However, no recommendation for the treatment of resectable gastric cancer could be proposed because of the heterogeneity of the methodology used in these meta-analyses including studies with a small number of patients, and because old chemotherapy regimens were often followed in these trials. Several clinical studies have focused on chemotherapy drugs that are currently used in the clinical practice. For instance, in France, the randomized phase III trial of the French Federation of Digestive Oncology [Fédération Française de Cancérologie Digestive (FFCD)] on adjuvant chemotherapy combined with 5-fluorouracil (5-FU) and cisplatin (CDDP) after curative resection of gastric cancer showed no benefit on survival compared with surgery alone. In Japan, a randomized phase III trial on adjuvant chemotherapy with the 5-1 fluoropyrimidin derivative in patients with stage II-III GEA found that the 5-year overall survival (OS) rate was 71.7% in the S-1 arm compared with 61.1% in the surgery alone arm (HR = 0.68, 95%CI: 0.52-0.87, P = 0.003). More recently, the CLASSIC study reported a higher 5-year OS in patients with stage II or III gastric cancer who received adjuvant chemotherapy treatment with capecitabine plus oxaliplatin compared to patients who underwent only D2 gastrectomy (5-year OS rate: 78% vs 69%; HR = 0.58, 95%CI: 0.47-0.72, P < 0.0001).

Finally, a meta-analysis by the Global Advanced/Adjuvant Stomach Tumor RESEARCH International Collaboration (GASTRIC) Group that combined data from 3838 patients (17 trials) showed a benefit of 5-FU-based adjuvant chemotherapy vs surgery alone on OS (55.3% vs 49.6%, respectively; HR = 0.82, 95%CI: 0.76-0.90, P < 0.001) with stable results at 10 years (48% vs 40%, respectively).

For this reason, 5-FU-based adjuvant chemotherapy is now considered as a therapeutic option and has been included in the French National Thesaurus of Digestive Oncology (www.snfge.asso.fr) for patients with resected GEA.

Adjuvant chemoradiotherapy
The efficacy of adjuvant chemoradiotherapy after a R0 resection in GEA patients (stage I to IV M0) was studied with the SWOG 9008/INT 0116 phase III trial in 603 patients. They were randomized in two therapeutic arms: Surgery alone vs surgery combined with adjuvant chemoradiotherapy. The patients’ characteristics, including the tumor stage, were similar in the two groups: 65% of patients had pT3/T4 stage tumors and 85% N+ stage tumors. Treatment started with chemotherapy (1 cycle of the FUFOL Mayo Clinic regimen) followed with chemoradiotherapy after 1 mo. Radiotherapy was delivered in 25 fractions (45 Gy each) and FUFOL was administered during the first 4 d and the last 3 d of irradiation. Two additional FUFOL cycles were then given 1 mo after the end of chemoradiotherapy. In this study, 64% of patients completed the therapeutic protocol. The digestive and hematological toxicity rates were respectively of 33% and 54%. The administration of adjuvant chemoradiotherapy resulted in an improvement of the 5-year OS rate compared with surgery alone (40% vs 26%; HR = 1.31, 95%CI: 1.09-1.39, P = 0.005) and of the median disease-free survival (27 mo vs 19 mo; HR = 0.67, 95%CI: < 0.0001).
cycles of the FAMTX regimen (5-FU, doxorubicin and cisplatin) increased the proportion of patients with postoperative chemotherapy plus surgery arm, respectively. Although the trial was stopped early due to the small number of patients included (n = 59), the authors concluded to the poor efficacy of the FAMTX regimen in the treatment of resectable gastric cancer.

A randomized phase III trial compared in 503 patients with resectable stomach, lower esophagus or esophageal-gastric junction adenocarcinomas, surgery alone (n = 253) with perioperative chemotherapy (n = 250). This Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial comprised the ECF regimen (50 mg/m² epirubicin on day 1, 60 mg/m² CDDP on day 1 and continuous venous infusion of 5-FU, 200 mg/m² per day, for 3 wk). Three cycles were administered pre- and post-surgery, which took place within the 6 wk after randomization for patients in the surgery group, or 3 to 6 wk after the third chemotherapy cycle for the perioperative chemotherapy group. The surgical procedure, which was left to the surgeon's discretion, included D1 or D2 lymphadenectomy. The patients' characteristics were similar in both arms; 26% of patients had a lower esophageal or gastroesophageal junction tumor. In the chemotherapy arm, 86% of patients completed the neoadjuvant treatment, 55% initiated postoperative treatment and 42% completed the chemotherapy protocol. Concerning surgery, 88% and 95% patients underwent the intervention in the chemotherapy and surgery alone arms. The pathological analysis of the resected specimens showed significant tumor downsizing in the chemotherapy group compared to the surgery alone arm (mean tumor size: 3 cm vs 5 cm; P < 0.001). An improvement of T stage (P = 0.009) and N stage (P = 0.01) was also reported in the chemotherapy group. The 79% R0 resection rate was significantly higher in the chemotherapy arm than in the surgery alone group (70%; P = 0.03). Grade 3-4 hematological toxicities during pre- and postoperative chemotherapy were not significantly different in the two groups, with 24% and 28% of neutropenia, respectively. With a median follow-up of 3 years, the median OS was 24 mo vs 20 mo in the chemotherapy and surgery alone groups, respectively (HR = 0.75, 95%CI: 0.60-0.93, P = 0.009) and the 5-year survival rates were 36% and 23%, respectively. Progression-free survival was significantly longer in the chemotherapy than in the surgery alone group (HR = 0.66, 95%CI: 0.53-0.81, P = 0.0001) (Table 1). The therapy efficacy was independent of the tumor site. The ECF chemotherapy regimen was chosen based on the results of a phase III trial that compared the ECF and FAMTX regimens in patients with advanced GEA. In this study, ECF was associated with better response rate (45% vs 21%; P < 0.001), better median OS (8.7 mo vs 6.1 mo) and acceptable hematological toxicity (grade 3-4 neutropenia: 36% vs 58%) compared to FAMTX. Recently, a meta-analysis showed that addition of an anthracycline to the CDDP and 5-FU regimens increased the OS of patients with advanced disease, but this

**NEOADJUVANT SYSTEMIC THERAPIES IN GEA**

The choice of administering systemic chemotherapy to the patients before surgery of resectable GEA is mainly based on the possibility of improvement of the R0 resections and primary tumor downstaging/downsizing. Systemic neoadjuvant therapy may also remove occult micro-metastatic disease and facilitate the preoperative chemo-sensitivity assessment. Possible disadvantages of neoadjuvant systemic therapies include the risk of micro-metastatic disease and facilitate the preoperative toxicity and the difficulty of assessing the preoperative treatment response.

In all clinical trials, patients with gastric, gastro-esophageal junction and lower esophagus adenocarcinomas were considered together as a single population. In this review, we will distinguish the different tumor sites, and, concerning esophageal cancer, we will focus on the results of neoadjuvant chemoradiotherapy.

**Neoadjuvant chemotherapy**

The feasibility of neoadjuvant chemotherapy as treatment of resectable gastric cancers was initially shown in phase II studies, which reported an acceptable toxicity and no increase of the surgical mortality and morbidity rates using this therapeutic approach. The R0 resection rates following neoadjuvant chemotherapy were of 61% and 77%, with or without intra-peritoneal chemotherapy, respectively.

A randomized clinical trial coordinated by the Dutch Gastric Cancer Group, compared two groups of patients who underwent surgery alone (n = 30) or received neoadjuvant chemotherapy after surgery (n = 29), i.e., 4 cycles of the FAMTX regimen (5-FU, doxorubicin and methotrexate). The R0 resection rates were 62% vs 56% in the surgery alone arm and in the neoadjuvant chemotherapy plus surgery arm, respectively.
Table 1  Two neoadjuvant chemotherapy schedules offered for the treatment of resectable gastroesophageal adenocarcinomas

|                  | MAGIC (n = 304) |            | FNCLCC-FFCD (n = 304) |            |
|------------------|-----------------|------------|------------------------|------------|
|                  | ECF n = 250     | Surgery n = 253 | P                      | FP n = 113 | Surgery n = 111 | P                      |
| Median age, yr (range) | 62 (29-85)     | 62 (23-81) | 85 (36-75)           | 63 (38-75) |
| Sex, male (%)     | 82%             | 76%        | 74%                   | 74%        |
| Performance status, 0/1 | 68/32           | 68/32      | 74/26                 | 75/25      |
| Gastric ADK (%)   | 74%             | 74%        | 25%                   | 24%        |
| GOJ ADK (%)       | 26%             | 26%        | 75%                   | 76%        |
| Downstaging/downsizing (%) | 52%            | 38%       | 0.09                  | 42%        |
| T1/T2            | 48%             | 62%        | 58%                   | 68%        |
| N0/1             | 84%             | 76%        | (N0) 33%             | 20%        |
| N2/N3            | 16%             | 29%        | (N2) 67%             | 80%        |
| R0 resection rate (%) | 79%            | 70%       | 0.03                  | 84%        |
| 5-yr overall survival rate (%) | 36%            | 23%       | 0.009 (HR = 0.75)    | 38%        |

ADK: Adenocarcinomas; GOJ: Gastro-esophageal junction; ECF: Epirubicin, cisplatin and 5-FU; FP: 5-fluorouracil and cisplatin; MAGIC: Medical research council; FNCLCC-FFCD: Fédération nationale des centres de lutte contre le cancer - fédération française de cancérologie digestive.

advantage was not reported in the GASTRIC meta-analysis that combined data from 3226 patients.[16,28]

A recently published French trial (FNCLCC 94012-FFCD 9703) evaluated another perioperative (two neoadjuvant cycles and four postoperative cycles) chemotherapy regimen (continuous protracted intravenous infusion of 5-FU 800 mg/m² per day from days 1 to 4 and 100 mg/m² CDDP on day 1 or 2 every 4 wk).[29] It included 224 patients who were randomized between perioperative chemotherapy (n = 113) and surgery alone (n = 111). Patients underwent surgery 4 to 6 wk after neoadjuvant chemotherapy, and postoperative chemotherapy started 4 to 6 wk after surgery. The patients’ characteristics were similar in the two groups. The originality in this study was the high percentage (75%) of patients with tumor in the cardia and in the lower esophagus. Preoperative staging was evaluated by endoscopic ultrasound examination and CT scan. In the perioperative chemotherapy arm, 96% underwent surgery compared with 99% in the surgery alone arm, and 87% of patients completed neoadjuvant chemotherapy. The pathological assessment of the resected specimens was similar in the two groups in terms of pT, whereas slightly less tumors were classified as N+ in the chemotherapy arm than in the surgery alone arm (67% vs 80%; not significant difference). The R0 resection rate was of 87% in the chemotherapy group, higher than the 74% rate in the surgery alone arm (67% vs 80%; not significant difference). OS was comparable between the two arms, but this study lacked statistical power due to recruitment failure (expected patients per arm = 180; patients included in each arm = 72).[30]

The MAGIC and the FNCLCC 94012-FFCD 9703 studies reported similar benefits as those of the MRC OE02 trial that assessed the effect of CDDP (80 mg/m² administered by intravenous infusion for 4 h on day 1, day 1 = day 21) and 5-FU (1000 mg/m² by continuous protracted venous infusion from days 1 to 4, day 1 = day 21) in patients with resectable esophageal cancer.[31] In this study, 802 patients (66% had tumors located in the lower portion of the esophagus or in the cardia) were randomized in two arms, surgery alone (n = 402) vs preoperative chemotherapy (n = 400). The median OS was significantly higher in the chemotherapy group (17 mo vs 13 mo; 95%CI: 30-196 d) as well as the 5-year OS (23% vs 17%; HR = 0.84, 95%CI: 0.72-0.98, P = 0.03) according to the updated results.[32]

At the 2015 ASCO annual meeting, Alderson et al.[33] reported the results of the OE05 trial that compared the ECX (4 cycles, n = 446) and 5-FU with CDDP (2 cycles, n = 451) regimens as neoadjuvant chemotherapy in patients with resectable adenocarcinoma of the esophagus or of gastroesophageal junction (Siewert type I and II). No significantly survival difference was observed between treatments even when an anthracycline was added to the CDDP and 5-FU regimen [3-year OS: 42% (95%CI: 37-46) in the 5-FU/CDDP arm vs 39% (95%CI: 35-44) in the ECX arm; HR = 0.92, 95%CI: 0.79-1.08, P = 0.8]. However, grade 3-4 toxicities were more frequent in patients treated with ECX (diarrhea, neutropenia, hand-foot syndrome and mucitis).

These two trials (MAGIC and FNCLCC 94012-FFCD 9703) were the first studies to demonstrate better survival rates with a perioperative systemic approach for the treatment of localized GEA (Table 1). These results
have been confirmed in the meta-analysis by Li et al[34]. and neoadjuvant chemotherapy is now considered as standard treatment for GEA in Europe. Moreover, based on the first OEO5 trial results, neoadjuvant chemotherapy with 5-FU and CDDP seems to be the best option in this setting.

**Neoadjuvant chemoradiotherapy**

Considering the improvement brought by systemic neoadjuvant chemotherapy for the management of patients with gastroesophageal junction and lower esophagus adenocarcinoma, several randomized phase II study assessed the benefit of neoadjuvant chemoradiotherapy compared to surgery alone. The clinical trials by Urba et al[35] and Burmeister et al[36] did not show any benefit of chemoradiotherapy compared with surgery concerning the 3-year OS rate (30% vs 16%; P = 0.16) and the median OS (21.7 mo vs 18.5 mo; P = 0.38), in a population of patients among whom 75% had a gastroesophageal junction or lower esophagus adenocarcinoma (Table 2).

Only one phase III trial found that chemoradiotherapy before surgery improved survival[37]. In this study, 113 patients with gastroesophageal junction and lower esophagus adenocarcinoma were randomized in two groups, Preoperative chemoradiotherapy plus surgery or surgery alone. Two cycles of 5-FU and CDDP were administered during radiotherapy, followed by surgery (multiple procedures) 8 wk after the beginning of the combined treatment. After a median follow-up of 10 mo, the median OS (16 mo vs 11 mo, P = 0.01) and the 3-year OS rates (32% vs 6%, P = 0.01) were significantly higher in the combined treatment arm than in the surgery alone arm, and the pathologic complete response rate was 25% in the chemoradiotherapy plus surgery arm. However, this monocentric study was closed prematurely after an intermediate analysis and with an unusually low survival rate in the surgery alone arm. Therefore, it is unclear how its results could be generalized.

The meta-analysis of 10 randomized trials (1209 patients) by Gebks et al[38] found an OS benefit of 13% at two years in patients treated with neoadjuvant chemoradiotherapy plus surgery vs surgery alone (HR = 0.81, 95%CI: 0.70-0.93, P = 0.002 and HR = 0.75, 95%CI: 0.59-0.95, P = 0.05) for the adenocarcinoma type in esophageal carcinoma. More recently, the CALGB Group reported a benefit of neoadjuvant chemoradiotherapy with a 5-FU-CDDP regimen in 56 patients (75% with a gastroesophageal or lower esophagus cancer)[39]. The 5-year OS rate was 39% in patients treated with neoadjuvant chemoradiotherapy compared with 16% (P < 0.008) in patients treated with surgery alone (median follow-up of 6 years). The complete pathologic response rate was 40%. These results are controversial due to the recruitment failure relative to the number of expected patients (n = 500).

Finally, the CROSS trial (n = 368 with esophageal or gastroesophageal junction cancer) clearly reported an improvement of the R0 resection rate (92% vs 69%; P < 0.0010) in patients treated with neoadjuvant chemoradiotherapy (paclitaxel-carboplatin regimen) plus surgery (n = 178) compared with patients who had only surgery (n = 188), with a complete pathologic response of 29%. The median OS was also significantly higher in the combined treatment arm than in the surgery arm (49 mo vs 24 mo; HR = 0.66, 95%CI: 0.49, 0.87, P = 0.003)[40].

**COMBINATION OF NEOADJUVANT INDUCTION CHEMOTHERAPY AND CHEMORADIOThERAPY**

Ajani et al[41] proposed a three-step strategy combining induction chemotherapy (two cycles of 5-FU, levofolinate and cisplatin) with preoperative chemoradiotherapy (45 Gy of radiation concomitantly with 5-FU) and surgery. Their phase II trial assessed response and survival in 33 patients with resectable gastric cancer. They showed a R0 resection rate of 70% and a 54% pathological response rate and a complete pathologic response of 30%. The median OS was 34 mo with a median follow-up of 5 years. The same authors assessed in another phase II trial the same three-step strategy adding paclitaxel to 5-FU during chemoradiotherapy[42]. The trial

| Trials         | Patients (n) | Pathology | CT-RT               | 5-yr OS rate (%) |
|----------------|-------------|-----------|---------------------|------------------|
| Walsh 1996     | CT-RT = 58  | ADK (100%)| CDDP-5FU            | CT-RT 32%        |
|                | S = 55      |           | 40 Gy               | S 6% (3-yr OS) (P = 0.01) |
| Urba 2001      | CT-RT = 50  | ADK (75%) | CDDP-5FU            | CT-RT 30%        |
|                | S = 50      |           | 45 Gy               | CT-RT 32%        |
| Burmeister 2005| CT-RT = 128 | ADK (62%) | CDDP-5FU            | S 16% (3-yr S) (P = 0.15) |
|                | S = 128     |           | 35 Gy               | CT-RT 22 mo      |
| Topper 2008    | CT-RT = 30  | ADK (75%) | CDDP-5FU            | CT-RT 39%        |
|                | S = 26      |           | 50.4 Gy             | S 16% (P = 0.008) |
| CROSS 2010     | CT-RT = 180 | ADK (75%) | Paclitaxel-carboplatin | CT-RT 47% |
|                | S = 188     |           | 41.4 Gy             | S 34% (P = 0.03) |

CT-RT: Chemoradiotherapy; OS: Overall survival; S: Surgery; ADK: Adenocarcinoma; SCC: Squamous cell carcinoma; VLB: Vinblastin.
included 49 patients with resectable gastric carcinoma and showed a 77% R0 resection rate and a complete pathologic response rate of 26%. A median OS of 23 mo was reported, with a median follow-up of 22 mo.

A similar strategy (neoadjuvant chemoradiotherapy after two or three cycles of 5-FU-cisplatin induction chemotherapy followed by surgery) was also evaluated in patients with T3/T4 GEA who were randomized in the three-step protocol group or in the neoadjuvant chemotherapy alone plus surgery group. Although the trial was stopped early due to poor accrual, there was a trend towards a higher efficacy in the three-step protocol arm than in the neoadjuvant chemotherapy arm (3-year disease-free survival rate: 47.7% vs 27.7%; HR = 0.67; 95%CI: 0.41-1.07; P = 0.07)\(^{[43]}\). An Australian randomized phase II study reported a significant reduction of the R1 resection rate in a similar population of patients treated with neoadjuvant chemoradiotherapy vs neoadjuvant chemotherapy alone (0% vs 11%, P = 0.04; pathological complete response rates of 31% vs 8%, respectively, P = 0.01)\(^{[44]}\).

**PERSPECTIVES IN THE GEA**

**MANAGEMENT: UNANSWERED QUESTIONS**

We described different treatment modalities and therapeutic strategies in the management of resectable GEA. However, some questions remain unresolved.

First, there is no strong evidence of the benefit of preoperative chemoradiotherapy over peroperative chemotherapy in patients with gastroesophageal junction adenocarcinoma. As surgical findings showed a higher incomplete tumor resection in locally-advanced T3/T4 gastroesophageal junction adenocarcinomas, the evaluation of the effects of preoperative chemoradiotherapy is urgently needed in this setting\(^{[45]}\). One ongoing phase III clinical trial is focusing on this question. The all-Ireland Cooperative Oncology Research Group trial is currently comparing preoperative chemoradiotherapy (as it was done in the CROSS study) and peroperative chemotherapy with the epirubicin, cisplatin and 5-FU (ECF) regimen. The Dutch Colorectal Cancer Group is currently assessing postoperative chemoradiotherapy, comparing perioperative epirubicin, cisplatin, capetabin (ECC) chemotherapy and preoperative ECC chemotherapy combined with postoperative chemoradiotherapy (the CRITICS study) in GEA.

Second, during chemotherapy/chemoradiotherapy, many patients experience life-threatening effects and cannot complete the treatment. Conroy et al\(^{[46]}\) showed that in patients with non-resectable esophageal carcinoma treated only with chemoradiotherapy, using oxaliplatin instead of CDDP (the FOLFOX4 regimen), reduced toxicities and toxic deaths compared with the standard 5-FU-CDDP regimen. A neoadjuvant FOLFOX6 chemotherapy regimen could be substituted to 5-FU-CDDP and proposed as ambulatory treatment.

In patients with metastatic GEA, the intensification of chemotherapy with docetaxel, 5-FU and cisplatin (TCF) is more effective than with 5-FU plus cisplatin alone, but with a significantly higher level of hematologic toxicities. The FLOT regimen (50 mg/m\(^2\) docetaxel and infusion of 5-FU, leucovorin and oxaliplatin (TEF regimen) was compared with 5-FU plus oxaliplatin (the FLO regimen) in a randomized phase II clinical trial. This study included patients older than 65 years and showed an improvement of the response rate and the progression-free survival in patients with locally-advanced cancer\(^{[47]}\). The combination of docetaxel, 5-FU, leucovorin and oxaliplatin as first-line treatment was effective with an intention-to-treat objective response rate of 66% (95%CI: 50.55-78.44) and two confirmed complete responses, progression-free survival of 6.3 mo (95%CI: 4.5-7.3) and OS of 12.1 mo (95%CI: 6.5-15.3)\(^{[48]}\). At the 2015 ASCO meeting, the authors presented preliminary results on the pathologic response in patients with resectable lower esophagus or gastroesophageal junction adenocarcinomas treated with FLOT or ECF. The complete pathologic response rate was significantly higher in patients who received FLOT than in those treated with ECF (15.6% vs 5.8%, P = 0.015)\(^{[49]}\).

For T3/T4 and or N+ GEA, using hyperthermic intraperitoneal chemotherapy (HIPEC) could reduce the frequent peritoneal recurrences in this setting. The PRODIGE French scientific group study is currently assessing HIPEC as adjuvant treatment.

Concerning targeted therapies, the use of trastuzumab combined with neoadjuvant chemotherapy is not recommended in patients with resectable GEA that overexpress HER2. Also, the MAGIC group is currently assessing the association of bevacizumab and the ECC (capetabin instead of 5-FU) chemotherapy regimen in a perioperative setting compared to chemotherapy with ECF alone.

Finally, we need predictive markers of neoadjuvant treatment response as early PET-scan metabolic response or assessment of biomarkers using systematic pre-therapeutic or liquid biopsies.

**CONCLUSION**

Currently, two main therapeutic options can be proposed for the treatment of resectable GEA: (1) adjuvant chemoradiotherapy (Macdonald et al\(^{[17]}\)) and (2) perioperative chemotherapy with 5-FU and platin salts-based regimens (Cunningham et al\(^{[49]}\) or Ychou et al\(^{[50]}\)). But what is best for our patients? Comparing the two strategies is not possible because the patients' profiles are too different. In both the MAGIC and FNCLCC 94012-FFCD 9703 trials, patients were identified at diagnosis, and not after surgery as it was done in the INT-0116 trial regarding the pT3/T4 or pN stage, the OMS (0 or 1) and the nutritional status.

Therefore, the treatment choice could be summarized...
between two unsatisfactory options: A preoperative approach in which patients with a good-prognosis tumor may be over-treated, or a postoperative approach in which patients with high risk of recurrence and poor nutritional status after surgery might be under-treated. We recommend deciding the therapeutic management of each individual patient in a multidisciplinary committee, before the primary tumor surgery. Future applications of cytotoxic therapies, e.g., oxaliplatin, capecitabine or docetaxel, or targeted therapies may help improving respectable GEA management.

For patients with gastroesophageal junction or lower esophagus adenocarcinomas, neoadjuvant chemoradiotherapy could be a viable option, but needs to be compared with perioperative chemotherapy.

ACKNOWLEDGMENTS

We thank Dr. Hélène de Forges for writing assistance and editorial help.

REFERENCES

1. Ferlay J, Soerjomataram I, Dias T, Lortet-Tieulent J, Ahmedini O, Bonis D, et al. Global cancer statistics 2012. CA Cancer J Clin 2015; 65: 87–108.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2002; 52: 23-48.
3. Blaze J, McKechnie K, Lumley J, McLean K, Lowson J, Leishman L, et al. Controversies in the treatment of local advanced rectal cancer: a systematic review and meta-analysis of randomised trials. Br J Surg 2013; 100: 211–223.
4. Busch D, van der Woude F, van der Meulen JP, Buyse M, Leemans CR, Lovegrove J, et al. A meta-analysis of randomised controlled trials of adjuvant chemotherapy compared with surgery alone for gastric cancer. Br J Cancer 2015; 113: 107–115.
5. Bonenkamp JJ, Boon MC, Bunt AM, Ohyama S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Higashino H, Yamamura Y, Kurita A, Arii K. Adjuvant chemotherapy for gastric cancer using S-1, an oral fluoropyrimidine. N Engl J Med 2001; 345: 1729–1737.
6. Crehange G,_serializer omitted, Roullet B, Bedenne L. Phase III trial of protracted compared with split course chemotherapy for esophageal carcinoma: Federation Francophone de Cancérologie Digestive 9102. J Clin Oncol 2007; 25: 4895–4901.
7. Siewert JR, Böttcher K, Roder JD, Busch R, Hermann P, Meyer HJ. Prognostic relevance of systematic lymph node dissection in gastric carcinoma. German Gastric Carcinoma Study Group. Br J Surg 1993; 80: 1015–1018.
8. Watanabe M, Tominaga S, Teds K. In: Cancer Treatment and Survival, Gann Monograph on Cancer Research. The Japanese Research Society for Gastric Cancer. Treatment results of gastric cancer patients: an analysis of nationwide database. Tokyo: Japan Sc Soc Press, 1995: 47–56.
9. Sundhala SA, Menck HR, Mansour EG, Winchester DP. The National Cancer Data Base report on gastric carcinoma. Cancer 1993; 70: 2333–2341.
10. Cohen DJ, Leichman LG. Controversies in the treatment of local and locally advanced gastric and esophageal cancers. J Clin Oncol 2015; 33: 1754–1759.
11. Hermans J, Bonenkamp JJ, Boon MC, Bunt AM, Ohyama S, Sasako M, Van de Velde CJ. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol 1993; 11: 1441–1447.
12. Earle CC, Maroun JA. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer 1999; 35: 1059–1064.
13. Mari E, Floriani l, Tinazzi A, Buda A, Belfiglio M, Valentini M, Cascini S, Barni S, Labianca R, Torri V. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell’Apparato Digenero). Ann Oncol 2000; 11: 837–843.
14. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2002; 52: 23-48.
15. Yang BJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, Mok JY, Kim YH, Ji J, Yeh TS, Button P, Sirzén F, Noh SH. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 2012; 379: 205–212.
16. Earle CC, Maroun JA. Adjuvant chemotherapy after curative resection for gastric cancer using S-1, an oral fluoropyrimidine. N Engl J Med 2001; 345: 1729–1737.
17. Macdonald JS, Smalley SR, Benedetti JK, Hundal SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725–730.
18. Smalley SR, Benedetti JK, Haller DG, Hundal SA, Estes NC, Ajani JA, Gunderson LL, Goldman B, Martenson JA, Jessup JM, Stemmermann GN, Blankle CD, Macdonald JS. Updated analysis of SWOG-directed intergroup study 0161: a phase III trial of adjuvant radiotherapy versus observation after curative gastric cancer resection. J Clin Oncol 2012; 30: 2237–2233.
19. Park SH, Sohn TS, Lee J, Lim do H, Hong ME, Kim KM, Sohn I, Jung SH, Choi MG, Lee JH, Bae JM, Kim S, Kim ST, Park JO, Park YS, Lim HY, Kang WK. Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses. J Clin Oncol 2015; 33: 3100–3108.
20. Braga M, Zuliani W, Foppa L, Di Carlo V, Cristallo M. Food intake and nutritional status after total gastrectomy: results of a nutritional follow-up. Br J Surg 1988; 75: 477–480.
21. Krook PS, Leichman CG, Leichman L, Tan M, Laine L, Stain S, Baranda J, Casagrande Y, Grosvenor, S, Silverman H. Systemic chemotherapy for gastric carcinoma followed by postoperative intraperitoneal therapy: a final report. Cancer 1997; 79: 1767–1775.
22. Kelsen D, Karpeh M, Schwartz G, Gerdes H, Litchodale C, Botet J, Lauers G, Klimstra D, Huang Y, Saltz L, Quan V, Brennan M. Neoadjuvant therapy of high-risk gastric cancer: a phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil. J Clin Oncol 1996; 14: 1053-1048.
Probst S, Rethwisch V, Stoehlmacher-Williams J, Prasnikar N, Hollerbach S, Bokemeyer C, Mahlberg R, Hofheinz RD, Luley K, Kullmann F, Jäger E. The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+). *Eur J Cancer* 2013; 49: 835-842 [PMID: 23063354 DOI: 10.1016/j.ejca.2012.09.025]

Pernot S, Mitry E, Samalin E, Dahan L, Dalban C, Ychou M, Seitz JF, Turki H, Mazard T, Zaanan A, Lepère C, Vaillant JN, Landi B, Rougier P, Taieb J. Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin (TEF) as first-line treatment for advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: safety and efficacy in a multicenter cohort. *Gastric Cancer* 2014; 17: 341-347 [PMID: 23739764 DOI: 10.1007/s10120-013-0266-6]

Pauligk C, Tannapfel A, Meiler J, Luley KB, Kopp HG, Hornam N, Hofheinz RD, Schmalenberg H, Probst S, Haag GM, Egger M, Behringer DM, Stoehlmacher J, Prasnikar N, Block A, Trojan J, Koenigsman M, Schmiegel W, Jäger E, Al-Batran SE. Pathological response to neoadjuvant 5-FU, oxaliplatin, and docetaxel (FLOT) versus epirubicin, cisplatin, and 5-FU (ECF) in patients with locally advanced, resectable gastric/esophagogastric junction (EGJ) cancer: Data from the phase II part of the FLOT4 phase III study of the AIO. 2015 ASCO Annual Meeting 2015; 33: 4016. Available from: URL: http://meetinglibrary.asco.org/content/147101-156

P- Reviewer: Kabir A, Kao J, Razis E  S- Editor: Kong JX
L- Editor: A  E- Editor: Wu HL
